Preclinical pharmacology of ciclesonide

European Respiratory Review

Volumn 13, Issue 90, 2004, Pages 66-68

  Belvisi, M G ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Ciclesonide; Inflammation; Inhaled corticosteroids; Lung targeted activation

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; GLUCOCORTICOID;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; BONE MASS; CONFERENCE PAPER; COUGHING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG RECEPTOR BINDING; DYSPHONIA; HUMAN; SIDE EFFECT;

EID: 3242671522     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. National Heart Lung and Blood Institute/World Health Organization. Workshop report: Asthma management and prevention: a practical guide for public health officials and health care professionals (2002). NIH Publication No. 02-3659. http://www.ginasthma.com/workshop.pdf; Date updated: April 2002, Date accessed: March, 2004.
2. Derendorf H, Hochhaus G, Meibohm B, Möllmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: Suppl. 4 Pt 2, S440-S446.
3. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148: Suppl. 4 Pt 2, S1-S26.
4. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-955.
5. Derendorf H. Relevant pharmacokinetic parameters for determining efficacy and safety in inhaled corticosteroids. Eur Respir Rev 2004; 13: 90, 62-65.
6. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51: 400-409.
7. Leach CL: Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999; 104: Suppl. 6, S250-S252.
8. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106: 1209-1226.
9. Dietzel K, Engelstatter R, Keller A. Ciclesonide: an on-site-activated steroid. Prog Respir Res 2001; 31: 91-93.
10. Drollmann A, Langdon C, Engelstätter R, Rathgeb F, Steinijans VW, Wurst W. Ciclesonide is effective in the treatment of bronchial asthma. Eur Respir J 2001; 18: Suppl. 33, 95s.
11. Postma DS, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001; 17: 1083-1088.
12. Weinbrenner A, Hüneke D, Zschiesche M et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87: 2160-2163.
13. Nave R, Bethke TD, Seiberling M, Steinijans VW, Zech K. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. Eur Respir J 2002; 20: Suppl. 38, 110s.
14. 14C-ciclesonide after oral and intravenous administration in healthy subjects. Eur Respir J 2002; 20: Suppl. 38, 109s.
15. Stoeck M, Riedel R, Hochhaus G, et al. In vito and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 2004; 309: 249-258.
16. Belvisi MG, Bundschuh DS, Stoeck M et al. Preclinical pharmacological profile of ciclesonide, a novel corticosteroid for the treatment of asthma. Am J Respir Crit Care Med 2001; 163: A589.
17. Stoeck M, Hatzelmann A, Belvisi MG, Foster ML, Bundschuh DS. In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cells. Eur Respir J 2001; 18: Suppl. 33, 95s.
18. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 623-630.
19. Tunek A, Sjodin K, Hallstrom G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 25: 1311-1317.
20. Nave R, Sättele N, Meyer W, Fuhrst R, Zech K. Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. Am J Respir Crit Care Med 2003; 167: A771.
21. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. Am J Respir Crit Care Med 2003; 167: A1510.
22. Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Zeit Wissensch 1992; 137: 161-167.
23. Belvisi MG, Bundschuh DS, Stoeck M, et al. Preclinical in vivo assessment of ciclesonide: a novel corticosteroid for the treatment of asthma. Eur Respir J 2001; 18: Suppl. 33, 95s.